Robert Dreicer
#141,687
Most Influential Person Now
Researcher
Robert Dreicer's AcademicInfluence.com Rankings
Robert Dreicerlaw Degrees
Law
#2548
World Rank
#3172
Historical Rank
Common Law
#110
World Rank
#119
Historical Rank
International Law
#590
World Rank
#736
Historical Rank
Robert Dreicerengineering Degrees
Engineering
#5333
World Rank
#6584
Historical Rank
Biomedical Engineering
#392
World Rank
#401
Historical Rank
Download Badge
Law Engineering
Why Is Robert Dreicer Influential?
(Suggest an Edit or Addition)Robert Dreicer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Sipuleucel-T immunotherapy for castration-resistant prostate cancer. (2010) (4808)
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial (2016) (2837)
- Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. (2008) (2023)
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. (2015) (1995)
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial (2017) (1477)
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016) (889)
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients (2009) (832)
- Treatment of Non‐Metastatic Muscle‐Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline (2017) (612)
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. (2018) (546)
- Zoledronic acid reduces skeletal‐related events in patients with osteolytic metastases (2001) (530)
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients (2008) (479)
- Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. (2011) (437)
- Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. (2007) (378)
- Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. (1994) (314)
- Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. (2007) (250)
- A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. (2011) (233)
- Conversion of abiraterone to D4A drives antitumor activity in prostate cancer (2015) (226)
- Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. (2014) (194)
- Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. (1997) (189)
- Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. (2009) (178)
- Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy (2010) (169)
- ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. (2013) (165)
- Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. (2018) (161)
- Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium (2004) (158)
- Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. (2017) (151)
- Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. (2012) (150)
- Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. (2008) (145)
- Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. (2008) (144)
- Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. (2004) (140)
- Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. (1994) (139)
- Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial (2018) (138)
- Appetite and cancer-associated anorexia: a review. (2004) (135)
- Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib (2012) (126)
- Phase 2 trial of sorafenib in patients with advanced urothelial cancer (2009) (117)
- Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. (2011) (117)
- Squamous Cell Carcinoma of the Bladder: A Clinicopathologic Analysis of 45 Cases (2007) (116)
- Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. (2015) (114)
- A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. (2014) (113)
- A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. (2008) (112)
- Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. (2020) (109)
- Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. (2001) (107)
- Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. (1996) (102)
- CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. (2020) (101)
- Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. (2015) (101)
- Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. (2018) (98)
- Second-generation interferons for cancer: clinical targets. (2000) (95)
- Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. (1994) (95)
- A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors (2011) (93)
- HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization (2011) (93)
- Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma (2014) (91)
- Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: A phase I/II, open-label study. (2010) (91)
- Lack of pathologic down‐staging with neoadjuvant chemotherapy for muscle‐invasive urothelial carcinoma of the bladder (2009) (89)
- Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer (2007) (89)
- A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors (2009) (87)
- Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. (2000) (87)
- The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo (2013) (82)
- The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. (2012) (81)
- Prospective Clinical Study of Precision Oncology in Solid Tumors. (2015) (81)
- MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure (2009) (80)
- Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896) (2002) (80)
- A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab (2008) (77)
- Systemic chemotherapy for advanced bladder cancer: update and controversies. (2006) (77)
- A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. (2015) (75)
- Phase 2 trial of epothilone B analog BMS‐247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800) (2007) (74)
- HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. (2008) (73)
- Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. (2011) (73)
- Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer (2007) (72)
- Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. (1994) (71)
- Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab (2010) (67)
- Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. (2017) (66)
- Chemotherapy for multiple myeloma (1984) (63)
- Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. (2020) (62)
- IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). (2016) (61)
- Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial (2016) (61)
- Association of percentage of tumour burden removed with debulking nephrectomy and progression‐free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy (2010) (60)
- Bladder cancer: narrowing the gap between evidence and practice. (2009) (58)
- Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. (2002) (57)
- Phase II study of lenalidomide in patients with metastatic renal cell carcinoma (2006) (54)
- Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC (2010) (54)
- Brain metastases from bladder carcinoma: presentation, treatment and survival. (2002) (54)
- Renal cell carcinoma for the nephrologist. (2018) (53)
- Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. (2007) (50)
- A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T (2014) (50)
- Neoadjuvant docetaxel treatment for locally advanced prostate cancer (2007) (50)
- A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer (2015) (48)
- Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel (2007) (47)
- Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. (2009) (46)
- Phase II Trial of GM-CSF in Advanced Prostate Cancer (2004) (46)
- Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. (2019) (45)
- Vinblastine, ifosfamide, and gallium nitrate—an active new regimen in patients with advanced carcinoma of the urothelium (1997) (44)
- Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma (2009) (43)
- Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. (2010) (42)
- HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. (2020) (40)
- Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. (2020) (40)
- Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium (2003) (39)
- Sunitinib‐induced macrocytosis in patients with metastatic renal cell carcinoma (2008) (39)
- Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer (2014) (39)
- Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 Trial). (2014) (39)
- Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. (2014) (39)
- Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study. (2011) (38)
- Incidence and management of testicular carcinoma metastatic to the neck. (1996) (37)
- Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: A phase I/II, open-label study (2013) (37)
- Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies (2006) (37)
- Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. (2019) (36)
- Granulocyte-macrophage colony-stimulating factor and vasculitis. (1989) (36)
- Presentation, location and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder (2008) (34)
- Olaparib for Metastatic Castration-Resistant Prostate Cancer (2020) (34)
- CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma. (2019) (34)
- Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. (2007) (34)
- Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. (2017) (34)
- Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. (2021) (33)
- Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study (2021) (33)
- Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. (2005) (33)
- Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). (2015) (32)
- A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer (2011) (32)
- Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. (2016) (32)
- Piritrexim in Advanced, Refractory Carcinoma of the Urothelium (E3896): A Phase II Trial of the Eastern Cooperative Oncology Group (2002) (32)
- Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer (2019) (32)
- Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial) (2014) (31)
- Society of Urologic Oncology position statement: Redefining the management of hormone‐refractory prostate carcinoma (2005) (31)
- Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group (2006) (30)
- Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210. (2018) (29)
- Phase II Trial of Suramin in Patients with Metastatic Renal Cell Carcinoma (2004) (28)
- Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. (2006) (28)
- The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib (2011) (27)
- Nonsecretory multiple myeloma (1982) (27)
- Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung. (1989) (27)
- Locally advanced and metastatic bladder cancer (2001) (26)
- Zibotentan for the treatment of castrate-resistant prostate cancer (2010) (26)
- Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. (2014) (26)
- Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. (2006) (25)
- A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). (2016) (25)
- A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer (2011) (25)
- Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study. (2020) (25)
- Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study. (2011) (24)
- Cessation of vascular endothelial growth factor–targeted therapy in patients with metastatic renal cell carcinoma (2012) (24)
- Clinical and immunomodulatory effects of bevacizumab and low‐dose interleukin‐2 in patients with metastatic renal cell carcinoma: results from a phase II trial (2011) (23)
- Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. (2004) (22)
- Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802) (2008) (22)
- Perioperative methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for poor risk transitional cell carcinoma of the bladder: an Eastern Cooperative Oncology Group pilot study. (1990) (21)
- Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study. (2020) (21)
- Phase II trial of sorafenib in advanced carcinoma of the urothelium (E 1804): A trial of the Eastern Cooperative Oncology Group (2008) (21)
- Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. (2014) (21)
- Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors (2007) (20)
- CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors (2019) (20)
- Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). (2022) (20)
- The atypical urothelial cancer patient: management of bladder cancers of non-transitional cell histology and cancers of the ureters and renal pelvis. (2007) (20)
- Preliminary observations of single-agent docetaxel as neoadjuvant therapy for locally advanced prostate cancer. (2001) (20)
- Sunitinib and bevacizumab in advanced solid tumors: A phase I trial (2008) (19)
- Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): Safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy (2008) (18)
- Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance) (2021) (18)
- A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer. (1997) (18)
- Gemcitabine and docetaxel in metastatic, castrate‐resistant prostate cancer (2011) (18)
- A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. (1997) (17)
- Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (mUC). (2016) (17)
- A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC) (2018) (17)
- A Phase II Study of 13-cis Retinoic Acid Plus Interferon α-2a in Advanced Stage Penile Carcinoma: An Eastern Cooperative Oncology Group Study (E3893) (2003) (17)
- A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC). (2014) (17)
- The evolving role of hormone therapy in advanced prostate cancer. (2000) (17)
- Hormonal therapy for prostate cancer: primum non nocere. (2002) (17)
- Neoadjuvant cisplatin, methotrexate and vinblastine for muscle-invasive bladder cancer: long-term followup. (1993) (17)
- T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during sunitinib treatment: Correlations with clinical responses and T helper 1/T helper 2 (Th1/Th2) bias. (2006) (17)
- Second-line chemotherapy for advanced urothelial cancer: because we should or because we can? (2009) (16)
- Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer (2019) (16)
- High-dose cytosine arabinoside in multiple myeloma. (1984) (16)
- Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial. (2014) (16)
- Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study. (2018) (16)
- High total dose 5-fluorouracil treatment during pregnancy. (1991) (16)
- Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm. (2011) (16)
- Paraneoplastic erythrocytosis in a young adult with an erythropoietin-producing Wilms' tumor. (1992) (16)
- Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma (2008) (15)
- Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. (2021) (15)
- Vaccine immunotherapy with MVA-Muc1-IL2 (TG4010) in prostate cancer patients with biochemical failure (2005) (15)
- Defining "cisplatin ineligible" patients with metastatic bladder cancer. (2011) (15)
- Clinical and Immunomodulatory Effects of Celecoxib Plus Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients with COX-2 Tumor Immunostaining (2011) (15)
- Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma (CPPCA): Preliminary results of a phase II trial (2008) (15)
- A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy. (2012) (14)
- Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer (2018) (14)
- Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy. (2015) (14)
- A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma (2012) (14)
- Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005? (2005) (14)
- DNA ploidy and P-glycoprotein expression as predictive factors of response to neoadjuvant chemotherapy for invasive bladder cancer. (1994) (14)
- 21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210) (2015) (14)
- Management of prostate and bladder cancer in the elderly. (1996) (14)
- Myelodysplastic syndrome and acute myeloid leukemia secondary to mitolactol treatment in patients with breast cancer. (1989) (14)
- Steroid hormone agonists and antagonists in the treatment of cancer. (1992) (14)
- New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches. (2011) (14)
- Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. (2004) (14)
- Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer. (2008) (14)
- Clinical and Biological Effects of Neoadjuvant Sargramostim and Thalidomide in Patients with Locally Advanced Prostate Carcinoma (2008) (14)
- Metastatic prostate cancer: assessment of response to systemic therapy. (1997) (13)
- A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer (2013) (13)
- Safety of VEGF-targeted tyrosine kinase inhibitors in patients (Pts) with metastatic renal cell carcinoma (mRCC) and central nervous system (CNS) metastases (2007) (13)
- Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease (2011) (13)
- Prostate Cancer Mortality After Radical Prostatectomy (2009) (13)
- A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors (2007) (13)
- Adjuvant and neoadjuvant chemotherapy for bladder cancer: management and controversies (2005) (12)
- Phase I/II trial of subcutaneous interleukin‐2, granulocyte‐macrophage colony‐stimulating factor and interferon‐α in patients with metastatic renal cell carcinoma (2012) (12)
- Intermittent Androgen Deprivation Therapy for Metastatic Prostate Cancer (2013) (12)
- Critical analysis of contemporary clinical research in muscle‐invasive and metastatic urothelial cancer (2013) (12)
- Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer (2019) (12)
- Differential Immunologic and MicroRNA Effects of 2 Dosing Regimens of Recombinant Human Granulocyte/Macrophage Colony Stimulating Factor (2012) (12)
- Phase I/II trial of GM-CSF and lenalidomide in patients with hormone refractory prostate cancer (HRPC) (2007) (11)
- Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. (2019) (11)
- Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. (2019) (11)
- Sunitinib in patients (pts) with unresectable primary renal cell carcinoma (RCC). (2016) (11)
- Phase Ι trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease (2008) (11)
- Drug Holiday in Metastatic Renal‐Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors (2018) (11)
- Locally advanced prostate cancer (2001) (11)
- New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab. (2018) (11)
- Vinblastine, ifosfamide, gallium nitrate, and filgrastim in platinum- and paclitaxel-resistant ovarian cancer: a phase II study. (1998) (11)
- Surgical resection of metastatic renal cell carcinoma: The University of Iowa experience. (1997) (11)
- Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. (2008) (11)
- KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC). (2016) (11)
- Everolimus for Advanced Renal Cell Carcinoma (2008) (10)
- Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC). (2012) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Phase II trial of pemetrexed disodium and gemcitabine in advanced carcinoma of the urothelium (E4802): A trial of the Eastern Cooperative Oncology Group (2007) (10)
- Chemotherapy for advanced urothelial cancer: end of the beginning? (2017) (10)
- Immune response from STRIDE, a randomized, phase 2, open label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC). (2015) (10)
- Maintenance sunitinib postchemotherapy (CT) in patients (pts) with advanced urothelial carcinoma (UC): A randomized placebo controlled phase II trial. (2016) (10)
- Phase I trial of thalidomide and Interleukin-2 in patients with metastatic renal cell carcinoma (2006) (10)
- The role of radionuclide angiocardiography in the treatment of patients receiving doxorubicin-based chemotherapy: a reassessment. (1997) (9)
- Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects. (2003) (9)
- Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial. (2020) (9)
- How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer. (2014) (9)
- Adjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial. (2004) (9)
- Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma. (2013) (9)
- Paclitaxel plus gallium nitrate and filgrastim in patients with refractory malignancies: a phase I trial. (1998) (9)
- E-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent, Nonmetastatic Prostate Cancer Patients with Rising PSA Levels. (2003) (9)
- Outcomes of treatment cessation in select metastatic renal cell carcinoma (mRCC) patients. (2014) (9)
- Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC). (2015) (8)
- The future of drug development in urothelial cancer. (2012) (8)
- Association of percentage of tumor burden removed with debulking nephrectomy and progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC) patients (Pts) treated with VEGF-targeted therapy. (2009) (8)
- Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity. (2007) (8)
- Abiraterone for Castration-Resistant Metastatic Prostate Cancer (2011) (8)
- LBA24 Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study (2021) (8)
- Traditional approaches to androgen deprivation therapy. (2011) (8)
- Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET (2020) (8)
- Management of stage I nonseminomatous germ-cell tumors. (2002) (7)
- PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC). (2021) (7)
- Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. (2018) (7)
- Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study. (2012) (7)
- Chemotherapy for muscle-invasive bladder cancer in the perioperative setting: current standards. (2007) (7)
- Maximizing outcomes in genitourinary cancers across the treatment continuum (2011) (6)
- 774PSTRIDE, A RANDOMIZED, PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T WITH CONCURRENT VS SEQUENTIAL ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). (2014) (6)
- 651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC) (2021) (6)
- Phase I trial of pomalidomide given for patients with advanced solid tumors (2012) (6)
- Advanced bladder cancer: So many drugs, so little progress (2008) (6)
- Tolerability profile of ZD4054 is consistent with the effects of endothelin A receptor-specific antagonism (2005) (6)
- Hereditary implications of somatic tumor testing. (2015) (6)
- Systems pathology and predicting outcome after radical prostatectomy. (2008) (6)
- Phase II trial of epothilone B analogue BMS-247550 in advanced carcinoma of the urothelium (E3800): A trial of the Eastern Cooperative Oncology Group. (2006) (6)
- Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects. (2006) (6)
- Interdisciplinary management of locally advanced and metastatic genitourinary cancers: a team sport. (2015) (6)
- Sunitinib in BCG-refractory non-muscle-invasive transitional cell carcinoma of the bladder. (2011) (6)
- Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) (2018) (6)
- A pilot multicenter phase II study of adjuvant docetaxel (D) for high risk prostate cancer (PC) patients (pts) after radical prostatectomy (RP): Preliminary data (2005) (6)
- Burden of metastatic hormone-sensitive prostate cancer to identify men more likely to benefit from early docetaxel. (2017) (5)
- Correlation of increased eosinophil count following sipuleucel-T treatment with outcome in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). (2012) (5)
- Targeting the androgen receptor--theory and practice. (2011) (5)
- Phase II study of lenalidomide in patients (pts.) with metastatic renal cell carcinoma (MRCC). (2006) (5)
- Neoadjuvant Androgen-Deprivation Therapy for Prostate Cancer (2011) (5)
- Bridging the gap: Health disparity research initiatives through the department of defense (DOD) congressionally directed medical research programs (CDMRP) prostate cancer research program (PCRP) (2005) (5)
- Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel. (2014) (5)
- Controversies in the systemic management of patients with evidence of biochemical failure following radical prostatectomy. (2002) (5)
- Brachytherapy and continuous infusion 5‐fluorouracil for the treatment of locally advanced, lymph node negative, prostate cancer: A phase I trial (1996) (5)
- Neoadjuvant GM-CSF and thalidomide in men with high-risk prostate carcinoma undergoing radical prostatectomy. (2006) (5)
- Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study (2018) (5)
- Adjuvant Radiotherapy for Locally Advanced Prostate Cancer (2009) (4)
- 2526 Immune responses and clinical data from STRIDE, a randomized, phase 2, open label study of sipuleucel-T with concurrent vs sequential enzalutamide administration in metastatic castrationresistant prostate cancer (2015) (4)
- Androgen Deprivation Therapy for Localized Prostate Cancer (2014) (4)
- A phase II study of pazopanib (P) in patients (Pts) with localized renal cell carcinoma (RCC) to enable partial nephrectomy (PN). (2014) (4)
- Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer. (1989) (4)
- Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer. (1994) (4)
- Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC). (2021) (4)
- Lenalidomide: Immunomodulatory, antiangiogenic, and clinical activity in solid tumors (2007) (4)
- Palonosetron (PALO) + dexamethasone (DEX) for prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) in patients receiving multiple-day cisplatin CT for germ cell cancer. (2006) (4)
- Chemotherapy for advanced prostate cancer: docetaxel and beyond. (2006) (4)
- Indications and practice with androgen deprivation therapy. (2011) (4)
- A randomized placebo-controlled trial of daily high-dose oral risedronate in men with metastatic prostate cancer commencing androgen deprivation therapy (ADT). (2010) (4)
- Revisiting truth and consequences: what to do when the patient doesn't want to know. (2002) (4)
- Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC). (2019) (4)
- Continuous infusion, intravesical doxorubicin for the treatment of regionally advanced bladder cancer: a phase I-II trial. (1997) (4)
- Androgen-Deprivation Therapy and Cardiovascular Mortality (2011) (4)
- MP78-07 CLINICAL CHARACTERISTICS ASSOCIATED WITH EARLY PROGRESSION OR LONG-TERM RESPONSE FROM THE PHASE II IMVIGOR210 STUDY: ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (2018) (4)
- Long term toxicity of tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC) (2008) (4)
- Frequency and survival impact of osseous metastases in patients with untreated renal cell carcinoma. (2004) (4)
- A multicenter phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic castration-resistant prostate cancer (mCRPC), suitable for treatment with a taxane (NCT04028388). (2020) (4)
- Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer. (2001) (4)
- Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. (2022) (3)
- Focusing on testosterone. (2011) (3)
- 5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors. (2019) (3)
- Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in men with prostate cancer previously treated with taxane. (2012) (3)
- Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. (2020) (3)
- Identifying patients with node-positive prostate cancer who may benefit from adjuvant pelvic radiation following prostatectomy. (2012) (3)
- Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. (2015) (3)
- Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). (2022) (3)
- PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer (BC). (2019) (3)
- FIGHT-205: Phase II study of first-line pemigatinib (PEMI) plus pembrolizumab (PEMBRO) versus PEMI alone versus standard of care (SOC) for cisplatin (CIS)—Ineligible urothelial carcinoma (UC) with FGFR3 mutation or rearrangement. (2020) (3)
- Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined modality therapy for muscle-invasive bladder cancer: A pooled analysis of RTOG 9906 and 0233. (2014) (3)
- Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial. (2018) (3)
- Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib. (2014) (3)
- Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC). (2012) (3)
- Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group (2003) (3)
- Efficacy and toxicity of docetaxel in elderly men with castrate-resistant metastatic prostate cancer. (2010) (3)
- HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial. (2019) (3)
- Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials. (2017) (3)
- Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial). (2022) (3)
- Phase I trial of daily pomalidomide in patients with advanced solid tumors. (2010) (2)
- Overall survival after development of metastatic disease following local therapy in patients treated for localized prostate cancer in the PSA era (2003) (2)
- The authors reply. (2018) (2)
- GENE EXPRESSION PROFILING FOR THE PREDICTION OF THERAPEUTIC RESPONSE TO ADJUVANT DOCETAXEL FOR HIGH RISK LOCALIZED PROSTATE CARCINOMA (2008) (2)
- Phase II trial of edatrexate in patients with metastatic colorectal cancer (1995) (2)
- Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC) (2015) (2)
- Discrepancy between reported progressive disease per radiology report and treating oncologist tumor measurements in patients with metastatic renal cell carcinoma (mRCC) receiving sunitinib. (2012) (2)
- Diabetes and Mortality in Men with Prostate Cancer (2008) (2)
- Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy (2020) (2)
- New option for cisplatin-ineligible urothelial cancer. (2017) (2)
- 756OCHEMOHORMONAL THERAPY VERSUS HORMONAL THERAPY FOR HORMONE NAïVE HIGH VOLUME NEWLY METASTATIC PROSTATE CANCER (PRCA): ECOG LED PHASE III RANDOMIZED TRIAL. (2014) (2)
- Meta-analysis of randomized trials comparing cisplatin versus carboplatin-based regimens for the first-line therapy of metastatic transitional cell carcinoma of the urothelium (TCCU). (2011) (2)
- Paracolic recurrence of stage I seminoma. (2003) (2)
- Lower PSA at 7 months is prognostic for improved overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel (D). (2017) (2)
- 7014 POSTER DISCUSSION Evaluation of Circulating Tumour Cells (CTCs) in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Receiving TAK-700, an Investigational 17,20-lyase Inhibitor (2011) (2)
- Impact of metformin on prostate cancer (PC) outcomes in the E3805 CHAARTED trial. (2017) (2)
- Inhibition of the IGF pathway in metastatic castrate resistant prostate cancer (CRPC): Results from a phase II study of OSI-906 (linsitinib). (2013) (2)
- Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC) (2019) (2)
- Clinical activity of abiraterone acetate in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. (2014) (2)
- Evolving Role of Genomics in Genitourinary Neoplasms. (2019) (2)
- A phase II study of linsitinib (OSI-906) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). (2013) (2)
- Treatment patterns and economic burden of illness in patients with advanced bladder cancer receiving second-line therapy. (2017) (2)
- Why Do Obese Men Have Lower PSA Concentrations (2007) (2)
- Circulating tumor cells (CTCs) and LDH as prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial. (2014) (2)
- Cancer pain management: 'inadequate'. (1994) (1)
- A Potential Biomarker for Resistance to Prostate Cancer Drugs (2014) (1)
- Cancer Therapy : Preclinical The Investigational Aurora Kinase A Inhibitor MLN 8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo (2013) (1)
- Abstract A055: Racial disparities in metastatic castrate-resistant prostate cancer (mCRPC): Evidence from the Veterans Health Administration (VHA) (2018) (1)
- Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis. (2019) (1)
- Adjuvant Radiotherapy for High-Risk Prostate Cancer (2012) (1)
- Original article Phase II trial of GM-CSF thalidomide in patients with androgen- independent metastatic prostate cancer (2005) (1)
- Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Speci fi c Antigen Across Five Randomized Phase III Clinical Trials (2018) (1)
- Causes of Death in Men with Prostate Cancer (2012) (1)
- Androgen-Deprivation Therapy for High-Risk Prostate Cancer (2011) (1)
- A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma. (2021) (1)
- 804PPractice patterns in metastatic castration-resistant prostate cancer (mCRPC): Evidence from the veterans health administration (2017) (1)
- Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer (2017) (1)
- Urothelial Carcinoma: Role of Perioperative Systemic Chemotherapy (2012) (1)
- A phase II trial of gemcitabine and docetaxel in hormone-refractory metastatic prostate cancer. (2006) (1)
- Cessation of VEGF-targeted therapy in patients with metastatic renal cell carcinoma (mRCC): Feasibility and clinical outcome. (2011) (1)
- Comparing Radiation Treatments for Localized Prostate Cancer (2012) (1)
- A five-year analysis of the New Investigator Award mechanism of the Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP) Prostate Cancer Research Program (PCRP) (2005) (1)
- 1589: Adjuvant Weekly Docetaxel for High-Risk Prostate Cancer Patients After Radical Prostatectomy (2005) (1)
- Sunitinib ReversesType-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients (2008) (1)
- MP70-20 A PHASE 2 TRIAL OF PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATE (PSMA ADC) IN TAXANE-TREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) (2014) (1)
- Effect of neoadjuvant docetaxel treatment for locally advanced prostate cancer on miRNA expression: A pilot study. (2012) (1)
- Effect of neoadjuvant docetaxel treatment for locally advanced prostate cancer on miRNA expression: A pilot study. (2012) (1)
- EDITORIAL COMMENT. (2019) (1)
- Managing advanced prostate cancer: the rapidly changing treatment landscape. (2014) (1)
- Phase I trial of docetaxel, carboplatin and lenalidomide in patients with advanced solid tumors. (2006) (1)
- ASN001, a novel CYP17 lyase inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Safety/tolerability and early activity in a multicenter phase 1/2 trial. (2016) (1)
- Phase I study of CNTO 95, a fully human monoclonal antibody to αv integrins, docetaxel, and prednisone in hormone refractory prostate cancer patients (HRPCP) (2007) (1)
- Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805 (2022) (1)
- Phase 2 randomized trial of ModraDoc006/r, oral docetaxel plus ritonavir, versus intravenous docetaxel in metastatic castration resistant prostate cancer (mCRPC). (2022) (1)
- Discrepancy between reported progressive disease per radiology report and treating oncologist tumor measurements in patients with metastatic renal cell carcinoma (mRCC) receiving sunitinib. (2012) (1)
- Single- vs. Multiple-Fraction Radiotherapy for Bone Metastases (2013) (1)
- EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma (2022) (1)
- New data, new paradigms for treating patients with prostate cancer: introduction. (2011) (1)
- 943. Prognostic Determinants Associated with Efficacy of Adenoviral p53 Gene Therapy in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (2006) (1)
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. (2019) (1)
- Androgen deprivation therapy in patients with advanced prostate cancer. (2010) (1)
- Macrocytosis in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKI's) (2007) (1)
- Meteorological design parameters for the candidate site of a radioactive-waste repository at Yucca Mountain, Nevada (1984) (1)
- PARP Inhibition in Advanced Prostate Cancer (2015) (1)
- Neoadjuvant chemotherapy for bladder cancer: current status (2003) (1)
- 870 A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (MCRPC) (2014) (1)
- Assessment of sarcopenia as predictor of response and outcome after neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC). (2015) (1)
- Immunomodulatory treatment in urothelial cancer. (2016) (1)
- Response to post-axitinib treatment in patients with metastatic renal cell carcinoma (2016) (1)
- Is Bevacizumab Safe for Patients with Brain Metastases (2010) (0)
- Long-Term Survival of Men Treated with Docetaxel and Prednisone for Prostate Cancer (2008) (0)
- Outcomes of Second Cancers in Men with Histories of Testicular Cancer (2007) (0)
- Does Hormonal Therapy for Prostate Cancer Raise Mortality Risk (2009) (0)
- Faculty Opinions recommendation of Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. (2006) (0)
- Intermittent vs. Continuous Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer (2012) (0)
- Is There an Optimal Treatment for High-Risk Prostate Cancer? (2018) (0)
- Risk-Adapted Management of Early-Stage Testicular Cancer (2009) (0)
- Androgen Deprivation Therapy Linked to Alzheimer Disease (2016) (0)
- Active Surveillance for Black vs. White Men with Low-Risk Prostate Cancer (2020) (0)
- Early Salvage Radiotherapy for Biochemical Recurrence After Prostatectomy (2016) (0)
- Postchemotherapy consolidative surgery for metastatic urothelial carcinoma. (2015) (0)
- Novel Immunotherapy for BCG-Unresponsive Bladder Cancer (2021) (0)
- Kidney Injury and Androgen Deprivation Therapy (2013) (0)
- Prostate Cancer Screening: Still No Mortality Benefit (2012) (0)
- ADT plus Radiation for Early, Localized Prostate Cancer (2011) (0)
- Inhibiting the Proteasome in Advanced Prostate Cancer (2006) (0)
- Do Undescended Testes Predict Testicular Cancer (2007) (0)
- ASCO 2021 Report — Genitourinary Cancers (2021) (0)
- Supplement Article Indications and Practice With Androgen Deprivation Therapy (2011) (0)
- Laparoscopic Prostatectomy: Experience Matters (2009) (0)
- Adjuvant Therapy for High-Risk Kidney Cancer: Paradigm Shift? (2021) (0)
- Partial or Radical Nephrectomy for Early-Stage Kidney Cancer? (2012) (0)
- Predicting Survival in Men with Metastatic Prostate Cancer (2006) (0)
- The association between the treatment-induced hypertension (Htn) and response to neoadjuvant sunitinib in renal cell carcinoma (RCC). (2012) (0)
- Selecting Appropriate Prostate Cancer Patients for Adjuvant Radiotherapy (2007) (0)
- A translational phase II trial of celecoxib plus interferon-alpha (IFN-α2b) in metastatic renal cell carcinoma (RCC) patients (pts) with 3+ COX-2 tumor immunostaining. (2009) (0)
- Biochemical Failure in Prostate Cancer: Managing Patients with Limited Data (2007) (0)
- Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer. (2003) (0)
- Dutasteride During Active Surveillance of Low-Risk Prostate Cancer (2012) (0)
- Conservative Management of Localized Prostate Cancer (2009) (0)
- Sunitinib for “Real World” Renal Cancer Patients (2009) (0)
- Original article Phase II trial of capecitabine and rHu-interferon--2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity (2007) (0)
- Long-Term Quality of Life Following Treatment for Localized Prostate Cancer (2020) (0)
- ASCO 2013 Report: Genitourinary Cancer (2013) (0)
- Deferred Treatment in Patients with Localized Prostate Cancer (2009) (0)
- What Are Risks for Second Cancers After Prostate Radiotherapy (2016) (0)
- Surrogate Endpoints for Prostate Cancer Survival (2009) (0)
- Are Multivitamin Use and Prostate Cancer Related (2007) (0)
- Zoledronic Acid During GnRH Therapy for Prostate Cancer (2007) (0)
- Bevacizumab plus Interferon for Advanced Renal Cancer (2008) (0)
- Cancer Prognostic Markers: User Beware (2007) (0)
- Timing of Postoperative Radiotherapy for High-Risk Prostate Cancer (2020) (0)
- Androgen Receptor Variant Not Predictive of Taxane Response in Prostate Cancer (2015) (0)
- Gene Mutations as a Target in Metastatic Prostate Cancer (2016) (0)
- Does Transdermal Estrogen Therapy for Prostate Cancer Decrease Cardiovascular Toxicities (2021) (0)
- Activity of Abiraterone Acetate in Patients with Castrate-Resistant Prostate Cancer (2010) (0)
- Response to post-axitinib treatment in patients with metastatic renal cell carcinoma (2016) (0)
- Thromboembolic Events in Men with Prostate Cancer (2010) (0)
- Percutaneous Ablation for Patients with Small Renal Cancers (2018) (0)
- Transitional Cell Carcinoma of the Renal Pelvis: Management (2008) (0)
- Androgen-Deprivation Therapy and MIs in Men with Prostate Cancer (2007) (0)
- Does Adding Paclitaxel to Chemotherapy Improve Urothelial Cancer Outcomes (2012) (0)
- Cardiovascular Risk in Prostate Cancer Patients Who Receive Hormone Therapy (2007) (0)
- Bone complications: an increasing risk in patients with prostate cancer. (2007) (0)
- Salvage Radiotherapy in Radical Prostatectomy Patients with PSA-Only Relapses (2008) (0)
- Are Disseminated Tumor Cells Prognostic in Prostate Cancer (2009) (0)
- Denosumab for Bone Metastases from Advanced Prostate Cancer (2011) (0)
- Sequence and Cross-Resistance: Challenges for Optimal Use of Next-Generation Anti-Androgen Therapies (2015) (0)
- Adjuvant Immunotherapy for High-Risk Bladder Cancer (2021) (0)
- Preventing Prostate Cancer with Finasteride: Effect on Sexual Function (2007) (0)
- Which Renal Cancer Therapy Do Patients Prefer (2014) (0)
- Olaparib for Men with Metastatic Castration-Resistant Prostate Cancer (2020) (0)
- Identifying patients with node-positive prostate cancer who may benefit from adjuvant pelvic radiation following prostatectomy. (2012) (0)
- Chemotherapy for Patients with Intermediate- and Poor-Risk Germ-Cell Tumors (2008) (0)
- Long-Term Survival Not Improved with ADT for Localized Prostate Cancer (2014) (0)
- Erectile Function After Prostate Cancer Therapy (2011) (0)
- Adjuvant Therapy for Adrenal Cancer (2007) (0)
- Cytoreductive Nephrectomy for Metastatic Kidney Cancer (2018) (0)
- Highlights in Genitourinary (Prostate) Cancer. (2016) (0)
- Using MRI to Detect Bone Metastases in High-Risk Prostate Cancer Patients (2007) (0)
- The Vaughn/Malkowicz article reviewed (2001) (0)
- Radium-223 Improves Survival in Advanced Prostate Cancer (2013) (0)
- Prognostic Implications for Patients with Gleason Tertiary Pattern 5 Prostate Cancer (2007) (0)
- Olaparib plus Abiraterone for Advanced Prostate Cancer (2018) (0)
- Effect of Radiation Dose in Treating Localized Prostate Cancer (2007) (0)
- ASCO 2017 Report — Genitourinary Cancer (2017) (0)
- Evolving Role of PSMA PET/CT in Clinically Localized Prostate Cancer (2021) (0)
- Liver Disease Associated with Androgen Deprivation Therapy (2018) (0)
- Pembrolizumab for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer (2017) (0)
- A Novel Antiandrogen to Treat Patients with Advanced Prostate Cancer (2010) (0)
- Short-Term vs. Long-Term Hormone Therapy for Prostate Cancer (2009) (0)
- Non–Muscle-Invasive Bladder Cancer (2009) (0)
- Is Less-Intensive Prostate Cancer Screening Appropriate? (2007) (0)
- Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer. (2019) (0)
- Radical Prostatectomy vs. Watchful Waiting (2008) (0)
- Management of Localized Prostate Cancer: Data at Last (2016) (0)
- Erlotinib plus Bevacizumab in Advanced Renal Cancer (2007) (0)
- Treatment Beyond Progression with Nivolumab in Advanced Renal Cancer (2017) (0)
- Adjuvant Cisplatin-Based Chemotherapy for High-Risk Bladder Cancer (2015) (0)
- Sunitinib vs. Interferon-α in Patients with Metastatic Renal Carcinoma (2007) (0)
- Adjuvant Radiotherapy for High-Risk Patients with Prostate Cancer (2006) (0)
- Open Versus Laparoscopic Radical Prostatectomy (2008) (0)
- Targeting Advanced Prostate Cancer Patients with PTEN Loss (2021) (0)
- Mutation Predicts Aggressive Prostate Cancer (2007) (0)
- Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer. (2003) (0)
- Axitinib Dose Titration for Advanced Renal Cancer (2013) (0)
- New, Unconfirmed Bone Lesions in Prostate Cancer Patients Receiving Enzalutamide (2019) (0)
- Immunotherapy plus Chemotherapy for Advanced Urothelial Cancer (2020) (0)
- Estimating Survival in Men with Localized Prostate Cancer (2011) (0)
- The European Prostate Cancer Screening Study: An Update (2012) (0)
- Prescribing preferences of U.S. oncologists for patients (Pts) with metastatic urothelial carcinoma (mUC) at first recurrence: Impact of novel agents. (2017) (0)
- Pazopanib: A New Tool for Advanced Renal Cancer (2010) (0)
- ASCO 2018 Report — Genitourinary Cancer (2018) (0)
- Therapy Options in Older Men with Prostate Cancer (2007) (0)
- Clinical and Biological Effects of Neoadjuvant Sargramostim and Thalidomide in Patients with LocallyAdvanced Prostate Carcinoma (2008) (0)
- PSA Velocity: A Criterion for Prostate Biopsy? (2011) (0)
- Faculty Opinions recommendation of Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. (2006) (0)
- How Active Should Active Surveillance Be for Prostate Cancer (2017) (0)
- Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer. (2015) (0)
- Alendronate’s Effect on Bone Loss in Men Treated with Hormonal Therapy for Prostate Cancer (2007) (0)
- Phase 3 VERACITY clinical study of sabizabulin in men with metastatic castrate resistant prostate cancer who have progressed on an androgen receptor targeting agent. (2022) (0)
- Sorafenib for Patients with Advanced Kidney Cancer (2007) (0)
- New Therapeutic Options for Advanced Kidney Cancer (2021) (0)
- High-Dose Chemotherapy for Advanced Germ-Cell Tumors (2007) (0)
- Early Docetaxel for Metastatic Prostate Cancer (2013) (0)
- Targeted 212Pb therapy in prostate cancer xenograft mouse model using a novel clinical-stage human monoclonal antibody (2022) (0)
- Selenium, Vitamin E, and Prostate Cancer (2009) (0)
- Genomic testing enhances treatment choices and clinical trial accrual in metastatic colorectal cancer (CRC): Results of a prospective clinical study. (2015) (0)
- CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment (2023) (0)
- Statins and Prostate-Specific Antigen Levels (2008) (0)
- Targeted Fusion–Guided Biopsy May Improve Detection of High-Risk Prostate Cancer (2015) (0)
- Finasteride for Chemoprevention of Prostate Cancer: The Story Continues (2007) (0)
- ASCO 2019 Report — Genitourinary Cancer (2019) (0)
- The Influence of Body Weight and C-Peptide Levels on Prostate Cancer Mortality (2008) (0)
- Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC). (2020) (0)
- Phase 2 study of pembrolizumab in patients with bacillus Calmette-Guérin–unresponsive, high-risk, non–muscle-invasive bladder cancer: KEYNOTE-057 (2018) (0)
- Pembrolizumab: Another Therapeutic Option for Advanced Kidney Cancer (2019) (0)
- Quality of Life Associated with Treatments for Prostate Cancer (2020) (0)
- Radiotherapy for Metastatic Prostate Cancer (2018) (0)
- Androgen Deprivation Therapy for Men with Prostate Cancer and Multiple Comorbidities (2015) (0)
- Second-Line Therapy for Advanced Renal Cancer (2011) (0)
- New Therapy for Castration-Resistant Prostate Cancer (2009) (0)
- Avelumab: Expanding the Armamentarium for Advanced Kidney Cancer (2019) (0)
- Adjuvant vs. Early Salvage Radiotherapy for High-Risk Prostate Cancer (2018) (0)
- Defining Clinical Endpoints in Castration-Resistant Prostate Cancer (2014) (0)
- Reply to C. Ren et al. (2018) (0)
- Second-Line Therapy for Advanced Urothelial Cancer (2017) (0)
- New Clinical Trial Data in Patients with Upper Tract Urothelial Cancer (2020) (0)
- A New Therapeutic Option for Advanced Urothelial Cancer (2021) (0)
- First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer. (2023) (0)
- Open vs. Minimally Invasive Radical Prostatectomy (2009) (0)
- Treatment-Related Pulmonary Toxicity in Germ Cell Cancer (2016) (0)
- An Oral Gonadotropin-Releasing Hormone Antagonist for Advanced Prostate Cancer (2020) (0)
- 1060: Neoadjuvant Docetaxel Prior to Radical Prostatectomy Induces a Significant PSA Response in Men with Locally Advanced Prostate Cancer: Results of a Phase II Trial (2004) (0)
- Seminar article Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer (2008) (0)
- Design of Phase II Oncology Trials (2007) (0)
- Sequencing of therapies in advanced prostate cancer. (2012) (0)
- ASCO 2020 Report — Genitourinary Cancer (2020) (0)
- Fractionated Radiotherapy for Prostate Cancer: Current Status (2019) (0)
- Adrenal Cortical Carcinoma and Pheochromocytoma (2018) (0)
- The role of bisphosphonates in prostate cancer: When you get to the fork in the road, take it (2004) (0)
- Sequential VEGFR-Targeted Therapy for Advanced Renal Cancer (2013) (0)
- Nivolumab vs. Everolimus for Advanced Renal Cancer (2015) (0)
- Radiation Therapy With or Without Hormonal Therapy for Prostate Cancer (2008) (0)
- Sirolimus Reduces Risk for Second Cancers After Kidney Transplant (2014) (0)
- Is There a Role for AR-V7 Testing in Prostate Cancer? (2017) (0)
- Nivolumab plus Ipilimumab for Advanced Renal-Cell Carcinoma (2018) (0)
- Surveillance for Stage I Testicular Cancer: How Effective? (2014) (0)
- Atezolizumab plus Bevacizumab for Advanced Renal Cell Cancer (2019) (0)
- Durability of complete response (CR) with atezolizumab (atezo) in locally advanced/metastatic urothelial carcinoma (mUC). (2019) (0)
- ASCO: Preview of the Prostate Cancer Sessions (2013) (0)
- The Role of Germline DNA Repair Mutations in Advanced Prostate Cancer (2019) (0)
- MRI-Targeted and Systematic Biopsy for Prostate Cancer Diagnosis (2020) (0)
- Prostate Cancer Molecular Subtypes: How Predictive or Prognostic? (2017) (0)
- The Impact of Prediagnosis 5-ARIs on Men with Prostate Cancer (2019) (0)
- Abiraterone Effective for Chemotherapy-Naive Prostate Cancer Patients (2012) (0)
- Predicting Survival in Men with Localized Prostate Cancer (2013) (0)
- GnRH agonists and prostate cancer. (1992) (0)
- Pharmacokinetic (PK) subgroup results from the phase 2 pharmacodynamic and bioequivalence study of abiraterone acetate fine particle formulation (AAFP) in patients with metastatic castration-resistant prostate cancer (mCRPC): The STAAR study. (2018) (0)
- Does Androgen-Deprivation Therapy Affect Physical Function? (2010) (0)
- No Role for Adjuvant Tyrosine Kinase Inhibitors in High-Risk Renal Cancer (2016) (0)
- 577. MVA-MUC1-IL2 Vaccine Immunotherapy for Patients Post-Prostatectomy with Rising PSA and No Evident Metastases (2004) (0)
- Immunotherapy for Advanced Prostate Cancer (2007) (0)
- Prostatectomy vs. Observation for Localized Prostate Cancer (2017) (0)
- An Intriguing New Agent for Advanced Prostate Cancer (2013) (0)
- ASCO 2014 Report — Genitourinary Cancer (2014) (0)
- Markers for Prostate Cancer Lethality (2009) (0)
- New mitomycin formulation for low-grade upper tract urothelial cancer. (2020) (0)
- A Treatment-Specific Predictive Biomarker in Metastatic Castration-Resistant Prostate Cancer (2016) (0)
- Characterizing Renal Masses with Iodine-124 PET-CT Imaging (2012) (0)
- Optimal Number of Docetaxel Cycles in Castration-Resistant Metastatic Prostate Cancer (2016) (0)
- Sex-Steroid Levels in Obese Men with Prostate Cancer (2007) (0)
- Improving Docetaxel’s Activity in Advanced Prostate Cancer (2007) (0)
- Reply to K. Lu. (2015) (0)
- Is There a Role for Checkpoint Inhibitors as Neoadjuvant Therapy in Bladder Cancer (2018) (0)
- Recent Developments in Chemotherapy for Bladder Cancer (2017) (0)
- With Radical Prostatectomy, the Experience of the Surgeon Matters (2007) (0)
- Current management of castration- resistant prostate cancer (CRPC) (2012) (0)
- Microsatellite Instability in Prostate Cancer and the Role of Immune Checkpoint Blockade (2019) (0)
- Combination Targeted Therapy for Patients with Advanced Renal Cancer (2010) (0)
- IMPACT OF METFORMIN ON PROSTATE CANCER PC OUTCOMES IN THE E3805 CHAARTED TRIAL: MP53‐07 (2017) (0)
- Early Experience with Anti-PD1 for Advanced Renal Cancer (2015) (0)
- Active Surveillance vs. Initial Treatment for Low-Risk Prostate Cancer (2010) (0)
- Phase IIClinicalTrial Design:Methods inTranslational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group (2006) (0)
- CT Scans in Surveillance of Stage I Nonseminomatous Testicular Cancers (2007) (0)
- Adjuvant Chemotherapy for Bladder Cancer (2010) (0)
- ASCO 2009 Report: Genitourinary Cancer (2009) (0)
- ASCO 2010 Report: Genitourinary Cancer (2010) (0)
- Ramucirumab plus Docetaxel After Platinum-Based Therapy for Advanced Urothelial Cancer (2020) (0)
- Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in men with prostate cancer previously treated with taxane. (2012) (0)
- Enzalutamide Before Chemotherapy for Prostate Cancer (2014) (0)
- Treatment of Nonseminomatous Germ Cell Tumors (2010) (0)
- Controversies in urologic oncology. (1991) (0)
- PSA Screening in Older Men (2006) (0)
- ASCO 2015 Report — Genitourinary Cancer (2015) (0)
- Androgen-Deprivation Therapy With or Without Chemotherapy (2009) (0)
- Adding Docetaxel or Zoledronic Acid to ADT for Advanced Prostate Cancer (2016) (0)
- Late Effects of Interventions for Localized Prostate Cancer (2013) (0)
- Dose-Dense Neoadjuvant Chemotherapy for Bladder Cancer (2014) (0)
- Do Patients with Familial Prostate Cancer Have Worse Outcomes (2008) (0)
- A phase 1/2a, open-label, multicenter study of intramuscular (IM) abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114). (2021) (0)
- What Is the Optimal Salvage Therapy for Patients with Relapsed Germ-Cell Tumors? (2007) (0)
- Apalutamide for Castration-Resistant PSA-Only Prostate Cancer (2018) (0)
- Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study (2016) (0)
- Second-Generation Antiandrogen for Advanced Prostate Cancer (2012) (0)
- Genitourinary Oncology: Prostate, Renal, and Bladder Cancer (2006) (0)
- A Multimodal Approach to Penile Cancer (2010) (0)
- Survival Benefit from mTOR Inhibition in Advanced Kidney Cancer (2007) (0)
- Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). (2023) (0)
- Osteoporosis and Fracture in Men with Prostate Cancer (2009) (0)
- Adjuvant Intravesical Gemcitabine for Low-Grade Bladder Cancer (2018) (0)
- Radiotherapy plus Androgen Deprivation for Recurrent Prostate Cancer (2017) (0)
- Targeting mTOR and VEGF in CRPC: Preliminary results of a phase I/II trial of temsirolimus (T) and bevacizumab (B) in docetaxel-refractory metastatic CRPC. (2012) (0)
- Comparing Chemotherapies for Adrenal Cancer (2012) (0)
- Combination Therapy for Metastatic Prostate Cancer (2017) (0)
- Androgen-Deprivation Therapy and Risk for Colorectal Cancer (2010) (0)
- Genomic testing to enhance treatment choices and clinical trial accrual in metastatic colorectal cancer: Results of a prospective cohort study. (2015) (0)
- Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancer (2020) (0)
- Cognitive Dysfunction with Androgen-Deprivation Therapy (2015) (0)
- Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1/2 clinical trial. (2017) (0)
- Immune cell repertoire in patients with indolent metastatic renal cell carcinoma. (2013) (0)
- A New Option for Advanced Prostate Cancer (2010) (0)
- Incremental Progress in Advanced Non–Clear-Cell Renal Cell Carcinoma (2021) (0)
- The Gleason Score: Does Order of Pattern Numbers Matter? (2009) (0)
- Detecting Metastatic Prostate Cancer with Prostate-Specific Membrane Antigen PET-CT (2020) (0)
- COX-2 Expression Might Be an Important Prognostic Marker in Prostate Cancer (2007) (0)
- Another Reason to Eat Your Vegetables: Effect on Risk for Aggressive Prostate Cancer (2007) (0)
- Systemic therapy for advanced adrenal cancer (2012) (0)
- Atezolizumab for Advanced Urothelial Cancer (2018) (0)
- Assessing an Imaging Technique in Bladder Cancer (2010) (0)
- Quality of Life Following Primary Therapy for Prostate Cancer (2008) (0)
- Next Generation Imaging: Impact on Postprostatectomy Salvage Therapy (2021) (0)
- Challenges with genomic testing in pancreaticobiliary cancers: Results of a prospective cohort study. (2015) (0)
- Extended Androgen-Deprivation Therapy for Prostate Cancer (2008) (0)
- New data, new paradigms for treating patients with prostate cancer. Conclusion. (2011) (0)
- Erratum: Cessation of vascular endothelial growth factortargeted therapy in patients with metastatic renal cell carcinoma. (Cancer (2012) DOI: 10.1002/cncr.26666) (2012) (0)
- How Much Will Cancer Care Costs Increase by 2020 (2011) (0)
- Editorial Comment. (2017) (0)
- Satraplatin in Advanced Prostate Cancer (2009) (0)
- Response Assessment in Castrate Progressive Prostate Cancer Trials: New PCWG Recommendations (2008) (0)
- Costs of Treatment: Fracture Prevention in Men Who Receive Androgen-Deprivation Therapy (2010) (0)
- Editorial comment. (2014) (0)
- Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC). (2017) (0)
- Utility of Radical Prostatectomy for Localized Prostate Cancer (2018) (0)
- Comparing Initial Agents for Metastatic Renal Cancer (2013) (0)
- Optimal Treatment for Men with Good-Prognosis Germ Cell Tumors (2010) (0)
- Association of tumor burden characteristics with outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. (2009) (0)
- Implications of Cardiovascular Disease for Prostate Cancer Patients Receiving Androgen-Signaling Inhibitors (2020) (0)
- Resistance to Enzalutamide for Metastatic Castration-Resistant Prostate Cancer (2018) (0)
- Urologists’ Patterns of Prescribing ADT for Prostate Cancer Patients (2007) (0)
- 865PTHE SIGNIFICANCE OF COMPLETE RESPONSE (CR) IN PATIENTS RECEIVING SALVAGE THERAPY FOR ADVANCED UROTHELIAL CARCINOMA (UC). (2014) (0)
- Impact of Exercise on Disease Progression in Men with Localized Prostate Cancer (2021) (0)
- Male-Factor Infertility and Germ-Cell Cancer (2009) (0)
- "Missing the target" in urothelial cancer. (2013) (0)
- Late Relapse of Germ-Cell Tumors (2009) (0)
- Bisphosphonates for Nonmetastatic Prostate Cancer (2007) (0)
- Influence of the Treating Physician in Low-Risk Prostate Cancer (2014) (0)
- 1142 Efficacy of atezolizumab (MPDL3280A) in platinum-treated metastatic urothelial carcinoma (mUC): Update from the IMvigor 210 phase II clinical trial (2016) (0)
- Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen? Reply (2018) (0)
- Multimodality Therapy for Locally Advanced Prostate Cancer (2019) (0)
- A Role for Statins in Metastatic Prostate Cancer (2015) (0)
- Radiotherapy for Prostate Cancer: Economic Considerations (2013) (0)
- Radiotherapy Matters for Locally Advanced Prostate Cancer (2011) (0)
- Circulating Tumor Cells in Advanced Prostate Cancer (2009) (0)
- Langmuir Probe Results on tile f/l'X Gun Experiment (2013) (0)
- Surgery vs. Observation for Early-Stage Prostate Cancer (2011) (0)
- Effect of Low-Dose Finasteride on Serum PSA Concentrations (2007) (0)
- Management of the Patient With Androgen-Independent Metastatic Prostate Cancer (2004) (0)
- 1658 METASTASECTOMY FOLLOWING TARGETED THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA (2010) (0)
- Enzalutamide vs. Bicalutamide for Advanced Prostate Cancer (2016) (0)
- ERCC1 and RRM1 expression patterns in synchronous primary and metastatic urothelial cancer lesions. (2011) (0)
- Long-Term Outcomes of Bladder-Sparing Therapy (2014) (0)
- Avelumab Maintenance Therapy for Metastatic Urothelial Cancer (2020) (0)
- MP6-08 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POMEGRANATE EXTRACT ON RISING PROSTATE SPECIFIC ANTIGEN (PSA) LEVELS IN MEN FOLLOWING PRIMARY THERAPY FOR PROSTATE CANCER (2015) (0)
- Enzalutamide for Hormone-Sensitive Metastatic Prostate Cancer (2019) (0)
- Testosterone Recovery After Limited Androgen Deprivation Therapy (2008) (0)
- Correlation of Renal Cancer Pathologic Type with Metastatic Sites and Survival (2021) (0)
- Post-axitinib systemic therapy in metastatic renal cell carcinoma (mRCC). (2012) (0)
- Active Surveillance for Localized Prostate Cancer: An Update (2015) (0)
- Combination Therapy for Advanced Renal Cancer (2015) (0)
- Symptoms and Survival in Advanced Prostate Cancer (2008) (0)
- Active Surveillance for Patients with Localized Prostate Cancer (2009) (0)
- Diabetes and Heart Disease in Men Who Receive Androgen-Deprivation Therapy (2006) (0)
- Castration-Resistant Prostate Cancer: Will Earlier Intervention Improve Outcomes? (2016) (0)
- Supplement Article Traditional Approaches to Androgen Deprivation Therapy (2011) (0)
- Lack of Utility of Combination Therapy for Advanced Clear Cell Renal Cancer (2015) (0)
- E-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent, Nonmetastatic Prostate Cancer Patients with Rising PSA Levels. (2003) (0)
- ASCO 2011 Report: Genitourinary Cancer (2011) (0)
- Phase IIb trial of oral ModraDoc006/r as a tolerable and effective option in comparison with intravenous docetaxel in metastatic castration-resistant prostate cancer (mCRPC). (2021) (0)
- Androgen-Deprivation Therapy plus Radiation Therapy for Prostate Cancer (2009) (0)
- Adjuvant vs. Salvage Radiotherapy for High-Risk Prostate Cancer (2020) (0)
- Active Surveillance of Favorable-Risk Prostate Cancer (2015) (0)
- Surveillance vs. Metastasis-Directed Therapy for Oligometastatic Prostate Cancer (2018) (0)
- Ramucirumab for Advanced Urothelial Cancer (2017) (0)
- 336 ALL HIGH-GRADE PROSTATE CANCERS CREATED EQUALLY? AN ANALYSIS OF CLINICAL FEATURES AND SURVIVAL AMONG PATIENTS WITH BIOPSY GLEASON SCORE 8, 9, AND 10 DISEASE (2012) (0)
- What Role for Radical Cystectomy for Muscle-Invasive Bladder Cancer? (2010) (0)
- Cabozantinib plus Nivolumab Improves Overall Survival in Advanced Kidney Cancer (2021) (0)
- Bone-Targeted Therapy for Hormone-Responsive Prostate Cancer (2014) (0)
- Sunitinib vs. Everolimus for Advanced Non–Clear-Cell Renal Cancer (2016) (0)
- Patient Perspectives on Toxicities Associated with Standard- and High-Dose Radiotherapy for Prostate Cancer (2010) (0)
- Platinum-Based Chemotherapy for Small-Cell Carcinoma of the Prostate (2013) (0)
- Drug Sequencing in Metastatic Castration-Resistant Prostate Cancer (2019) (0)
- Enfortumab Vedotin Improves Survival in Patients with Heavily Treated Metastatic Urothelial Cancer (2021) (0)
- Radiation Therapy for Metastatic Prostate Cancer (2016) (0)
- The Clinical Management of Prostate Cancer — The Medical Oncologist's Approach and Outcomes (2003) (0)
- in Bladder Cancer: The Next Chapter (2007) (0)
- Hormonal Therapy and Anxiety in Prostate Cancer Patients (2009) (0)
- Which Should Be Used First in Symptomatic Metastatic Castration-Resistant Prostate Cancer, Docetaxel or Radium? (2015) (0)
- Is There a Role for Adjuvant Therapy in High-Risk Renal Cancer? (2016) (0)
- Optimal Surgical Approach to Cystectomy: Open vs. Robot-Assisted (2018) (0)
- Nephrectomy for Metastatic Renal Cancer in the Age of Targeted Therapy (2016) (0)
- Phase 3 VERACITY clinical study of sabizabulin in men with metastatic castration-resistant prostate cancer who have progressed on an androgen receptor targeting agent. (2022) (0)
- Smoking Increases the Risk for Prostate Cancer Recurrence and Mortality (2011) (0)
- Survival Implications of Prostatectomy vs. Surveillance (2012) (0)
- Conservative management of localised prostate cancer (2009) (0)
- A Surrogate Marker for Prostate Cancer Survival (2008) (0)
- Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (2020) (0)
- ASCO 2016 Report — Genitourinary Cancer (2016) (0)
- Denosumab Delays Development of Bone Metastases in Prostate Cancer (2011) (0)
- Chemotherapy for the palliation of advanced prostate cancer (2008) (0)
- PD27-12 PRIMARY ANALYSIS OF IMVIGOR 210: ATEZOLIZUMAB IN PLATINUM-TREATED ADVANCED UROTHELIAL CARCINOMA (2016) (0)
- ASCO Practice Guidelines for Initial Hormonal Management of Prostate Cancer (2007) (0)
- 1591: Tumor Suppressor Gene Pten in Prostate Cancer: A Potential Therapeutic Target (2006) (0)
- Supplement Article Targeting the Androgen Receptor—Theory and Practice (2011) (0)
- A Radiographic Biomarker of Response in Prostate Cancer (2015) (0)
- Cabozantinib vs. Everolimus for Advanced Renal Cancer (2015) (0)
- High-Dose Chemotherapy for Patients with Poor-Risk Germ-Cell Tumors (2007) (0)
- Soy Supplementation Fails to Reduce Risk for Prostate Cancer Recurrence (2013) (0)
- Radical Prostatectomy vs. Observation for Early-Stage Prostate Cancer (2012) (0)
- ASCO 2012 Report: Genitourinary Cancer (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Robert Dreicer?
Robert Dreicer is affiliated with the following schools:
- Université de Montréal
- California Institute of Technology
- University of Siena
- University of Toronto
- University of Virginia
- University of Iowa
- Columbia University
- Massachusetts General Hospital
- Washington University in St. Louis
- Medical University of South Carolina
- Vanderbilt University
- Stanford University
- Case Western Reserve University
- Harvard University
